Preparation of HRT are available for delivery orally, transdermally, percutaneously, subcutaneous implant or vaginally or with an I.U.C.D. In addition, sublingual and intranasal spray options are being evaluated. In mainland Europe, injectable form of oestradiol is also available. At present in the UK, 'the only approved from of administration of testosterone to women is implantation. In reality, most women starting HRT-oral tablets will be the best option.
Oral
Oral Oestrogen is the most suitable initial therapy for most women, in the UK, for women with a uterus who are taking HRT over 80% take oral therapy. Now we have a wide range of natural oestrogen preparation containing oestradiol, oestrone, conjugated equine oestrogens and the synthetic steroid tibolone, which has oestrogenic androgenic and progestogenic activity.
After oral administration of oestradiol, there is extensive metabolism in the wall of the small intestine, and further changes occur on reaching the liver, so that only about 10% reaches the systemic circulation as oestradiol and much larger proportion as oestrone, oestrone sulphate or oestradiol glucuronide. Following oral oestrone there is similar result in circulation but with any oestrogen preparation up to 90% of the administered dose may be inactivated before reaching systemic circulation. Thus the dose administered oestrogen has to be correspondingly higher than that given by non oral routes to achieve the same effective blood levels. This so called "first pass" effect constitutes the major difference between oral and non-oral administration of oestrogen and has various clinical implication.
In postmenopansal women who is not taking HRT oestrone is the dominant oestrogen and there is an oestrdiol: oestrone ratio of about 0.2.
Oral preparation are: Oestrone based (Harmogen), oestradiol based (2 mg progynova), conjugated equine oestrogen (0.625 mg premarin) tibolone (livial 2.5 mg). Oestriol (Img ovestin), Kilogest (R)-28 tablets each containing 2 mg oestradiol and 1 mg norethesterone acetate. The semisynthetic oestrogen, ethinyl-oestradiol and mestranol, were developed primarily for oral contraception, and are generally considered less suitable for HRT. Mestranol and ethinyloestradiol are much cheaper than the more natural preparation but there is concern that their greater metabolic effect on the liver may result in an increased risk of venous and arterial thrombosis 11, 12 .
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Advantages and disadvantages of oral HRT administration

Advantages Disadvantages
•Easy to take, most people are used to swallowing tablets.
•Tablets are usually cheaper than other routes of administration.
•Good control due to short half life so can be withdrawn quickly.
•Wide choice of preparation available
•A high dose of oestrogen is required to overcome the extensive metabolism in the intestine and liver before reaching systemic circulation.
•Wide variation in absorption and metabolism during the 1st pass effect of intestine and liver.
•Alteration of some liver function and protein synthesis.
•Oral oestradiol is mainly converted to oestrone.
•Higher incidence of minor side effects than other routes.
•Requires daily dosage •All tablets contain lactose Transdermal oestrogen Oestrogen is well absorbed through skin and subcutaneous fat as well as vaginal epithaelium, nasal and sublingual mucosa. The main advantage of all these routes of administration is that metabolism in the liver and intestine is avoided. Pure oestradiol can therefore be administered directly into the systemic circulation and an oestradiol: oestrone ratio is similar to that found in premenopausal women:
Patches
The first skin patch Estraderm lTS Contains a reservoir of oestradiol with an alcohol solvent behind a rate limiting membrane and adhesive layer. Satisfactory circulating oestradiol levels are achieved but local skin reaction can be a troublesome side effect in upto 35% of women.
Newer transdermal systems consists of a single transparent matrix with an adhesive layer which contains oestradiol.
The dose delivered is proportional to the surface area of the patch in contact with the skin. 
Risk and contraindication to HRT
Risk is considered the denovo development of a potentially serious disease during and in consequence of the administration of HRT. A contraindication is regarded as the exacerbation by HRT of a pre-existing condition.
Endometrial cancer It has been known for over 20 years that use of oestrogen by itself without progestogen, in a women with a uterus increases the risk of endometrial hyperplasia, 7 cancer. The risk of endometrial hyperstimulation could be almost abolished by the addition of a progestogen and that the protective effect of progestogen depend not only upon daily dose but also upon the duration of administration each month. Maximal protective effect with sequential therapy were observed when the progestogen was added for 12-13 days each month.
Abnormal bleeding with HRT The causes and management of abnormal bleeding during HRT have recently been extensively reviewed (Spencer et aI1997). In a summary, two types of abnormal uterine bleeding are recognized with sequential therapies. The first is characterized by heavy or prolonged bleeding at the appropriate time of the cycle. The second type of abnormal bleeding is breakthrough bleeding and this can occur at any time. Tibolone offers a well tolerated therapy which is free from withdrawal bleeding, thus assuring compliance and long term benefits.
Breast cancer At present, there are no data on the association between breast cancer and use of HRT from randomized controlled trials. Stamfer from Nurses Health Study group has recently stated that use of mammographic services by HRT user in the Nurses Health Study population has been approximately 35-40% greater than use of these services by non-users of HRT. It is temptating to speculate that more frequent breast surveillance of HRT users results in earlier breast cancer detection with a reduced risk of death.
Ovarian cancer A more recent prospective, cohort study reported no increase in risk with ever use of HRT but observed an increase in risk when use of HRT has continued for 11 years or more.
Gallbladder disease
The largest study to have investigated the association between HRT and risk of gallbladder disease, the Nurses Health Study, reported a 1.5-2.0% increase in risk (Grodstein et al).
Furthermore, the risk of cholecystectomy in this study, increased with both oestrogen dose and also with duration of exposure. Non oral route oestrogens may not increase risk because they do not increase bile cholesterol saturation index, billiary salt composition, gallstone formation and after non surgical gallstone therapy, the non oral routes of HRT would be more suitable.
Malignant melanoma
Five studies have reported on the relationship between use of HRT and risk of malignant melanoma. One case controlled study reported a small increase in risk with long term use of HRT , but another case controlled study did not proof it. Thus if HRT increase the risk, than the impact is small.
Venous thrombosis
In November 1996, three studies were published reporting that HRT increased the risk of idiopathic venous thromboembolism. Several studies have shown that oral oestrogen increases coagulation activities but. causes other changes that might counteract this effect and the addition of progestogen may also be beneficial.
Transdermal oestrogen, however by avoiding the hepatic first pass effect, does not adversely affect coagulation. However, for a women who has had a VTE or other reasons at increased risk, the transdermal route might be preferable.
Lactose intolerance
People who are sensitive to lactose, may experience variable gastrointestinal and some systemic effects when ingested. Lactose is present as a bulking agent in all the currently available oral oestrogen preparation and all additional oral progestogen except for the progestogen only contraceptive pill Femulen which contains ethynodiol diacetate 500 microgm. This problem is avoided by all the non oral routes of administration.
Additional progestogen
The need to add progestogen to regimen of HRT for women with a uteres to protect the endometrium is well established and accepted. Many proprietory HRT preparations have contained 10-14 days either separately or combined in the daily tablets. Progestogens are now also incorporated in some matrix patch preparation in either a 28 day sequential regimen, Nuvelle TS and Evorel sequi or a continous combined regimen, Evorel conti.
Natural progesterone can also be administered via the vagina as a pessary, Cyclogest or a new gel, Cinone. This route avoides the first pass hepatic and intestinal metabolic effects and causes less side effects than with oral synthetic progestogens. The only proven merit of addition of progestogen is for prevention of endometrial hyperplasia and carcinoma. The levonorgestrol IUCD, Mirena which at present is only licensed in the UK, in combination with oestrogen, administered orally, transdermally or by implant.
Conclusion
All routes of administration of HRT are beneficial. For most women the oral route will be simplest, cheapest and most suitable for initial therapy. Thus the average women can now expect to spend approximately one third of her life in a postmenopausal state assuming normal age at menopause. Approximately 9.6 million, some 18% of the total population of the UK sensibly used HRT. HRT will improve the quality of life and prolong quantity. Oestrogen deficiency increases the risk of diseases with a high morbidity and mortality. HRT has been used for prevention and treatment of osteoporosis and also prevent cardiovascular diseases, urogenital atrophy, hot flushes, night sweating, loss of libido, psychological problem, dementia particularly Alzheimer's disease. Future development of intrauterine devices releasing progesterone, vaginal rings and the oral selective oestrogen receptor modulators (SERMS) will further increase the options so that few women will not be able to find some suitable therapy. Selective oestrogen receptor modulators (SERM) exemplified by naloxifen. Members www.orion-group.net/journals of this family show great potential as non hormonal alternative to existing oestrogen replacement therapy with better risk: benefit ratio and without the requirement for progestogens, nor the anxieties about breast cancer risk. In postmenopausal women, it increases bone mineral density, lowers serum lipids without stimulating endometrium.
